Looking forward to herd immunity
Tommy Williams
This week the “three pillars” continue to be front and center, though all have moved along with the calendar. Vaccines have the headlines with the one-shot Johnson & Johnson getting the go ahead from the FDA. The $1.9 trillion COVID relief stimulus package passed the House of Representative and moves to the Senate, where everyone expects it to be modified (lowered at least by the removal of $15/hour minimum wage component). Corporate earnings reports remain favorable, so, on balance the coast remains clear for favorable results in your investment account according to analysts at Nuveen Investments.